PulseNmore
7
0
0
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 7 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Home-Ultrasound in Routine High-Risk Care of Patients With Gestational Diabetes Mellitus (GDM)
Role: collaborator
Self Biophysical Profile Using a Home Ultrasound Device Proof of Concept
Role: lead
Detection of Lung Pathologies Among Dialysis Patients Using Pulsenmore MC™ Device - Feasibility Study
Role: lead
Human Factoring Validation of Pulsenmore ES Device
Role: lead
The Use of PulseNmore FC Device in Patients Undergoing IVF Treatment A Study to Evaluate the Safety and the Efficacy
Role: collaborator
Pulsenmore ES Device, Efficacy and Safety Assessment
Role: lead
Instinct™ Ultrasound Device Safety, Efficacy and Usability
Role: lead
All 7 trials loaded